Date: 2012-08-29
Type of information: Initiation of preclinical development
phase: 2
Announcement: dosing of the first patient
Company: Elan (Ireland)
Product: ELND005 (Scyllo-inositol)
Action mechanism:
Disease: bipolar 1 disorder
Therapeutic area: CNS diseases
Country: USA
Trial
details: The trial is a prospective, randomized, double-Blind, placebo-controlled, phase 2 safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with bipolar I disorder. It will enroll up to 400 patients (NCT01674010)
Latest
news: * On August 29, 2012, Elan has announced that it has commenced a Phase 2, placebo-controlled, safety and efficacy study of oral ELND005 as an adjunctive maintenance treatment in patients with Bipolar I Disorder (BPD 1) to delay the time to occurrence of mood episodes. The first patient has been dosed in the study. With the first patient now dosed in a Phase 2 trial, Transition Therapeutics Inc will receive a one time clinical milestone payment of $11 million.
